Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oncologix financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$332.5 K
2024-10-29
Revenue
$3.7 M
FY, 2014
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 |
|---|---|---|---|
| Revenue | 244.2K | 3.7M | |
| Cost of goods sold | 195.7K | 3.1M | |
| Gross profit | 48.5K | 614.4K | |
| Gross profit margin, % | 19.9% | 16.7% | |
| General and administrative expense | 130.8K | 329.7K | 1.1M |
| Operating expense total | 130.8K | 335.1K | 1.2M |
| Depreciation and amortization | 22.8K | ||
| EBIT | (131.2K) | (286.6K) | (571.8K) |
| EBIT margin, % | -117.3% | -15.5% | |
| Interest expense | 10.8K | 34.2K | 805.6K |
| Pre tax profit | (285.6K) | (653.4K) | (1.3M) |
| Income tax expense | (296.0K) | (956.0K) | |
| Net Income | (285.6K) | (653.5K) | (1.3M) |